vs
Beam Therapeutics Inc.（BEAM）与Eventbrite, Inc.（EB）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是Eventbrite, Inc.的1.6倍（$114.1M vs $73.5M），Beam Therapeutics Inc.净利率更高（214.1% vs -11.1%，领先225.2%），Beam Therapeutics Inc.同比增速更快（279.5% vs -3.9%），Eventbrite, Inc.自由现金流更多（$-60.9M vs $-87.0M）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
Eventbrite是源自美国的线下活动服务平台，为用户提供活动浏览、创建与推广服务，支持主办方免费在平台发布不限规模、不限数量的各类活动，是全球范围内活跃度较高的活动交易与推广平台。
BEAM vs EB — 直观对比
营收规模更大
BEAM
是对方的1.6倍
$73.5M
营收增速更快
BEAM
高出283.4%
-3.9%
净利率更高
BEAM
高出225.2%
-11.1%
自由现金流更多
EB
多$26.2M
$-87.0M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $73.5M |
| 净利润 | $244.3M | $-8.2M |
| 毛利率 | — | 68.1% |
| 营业利润率 | -15.3% | -12.4% |
| 净利率 | 214.1% | -11.1% |
| 营收同比 | 279.5% | -3.9% |
| 净利润同比 | 370.4% | 2.5% |
| 每股收益（稀释后） | $2.53 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMEB
| Q4 25 | $114.1M | $73.5M | ||
| Q3 25 | — | $71.7M | ||
| Q2 25 | — | $72.8M | ||
| Q1 25 | — | $73.8M | ||
| Q4 24 | — | $76.5M | ||
| Q3 24 | — | $77.8M | ||
| Q2 24 | — | $84.6M | ||
| Q1 24 | — | $86.3M |
净利润BEAMEB
| Q4 25 | $244.3M | $-8.2M | ||
| Q3 25 | — | $6.4M | ||
| Q2 25 | — | $-2.1M | ||
| Q1 25 | — | $-6.6M | ||
| Q4 24 | — | $-8.4M | ||
| Q3 24 | — | $-3.8M | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | — | $-4.5M |
毛利率BEAMEB
| Q4 25 | — | 68.1% | ||
| Q3 25 | — | 67.9% | ||
| Q2 25 | — | 67.5% | ||
| Q1 25 | — | 66.9% | ||
| Q4 24 | — | 68.2% | ||
| Q3 24 | — | 68.5% | ||
| Q2 24 | — | 70.9% | ||
| Q1 24 | — | 71.0% |
营业利润率BEAMEB
| Q4 25 | -15.3% | -12.4% | ||
| Q3 25 | — | -1.3% | ||
| Q2 25 | — | -8.7% | ||
| Q1 25 | — | -13.2% | ||
| Q4 24 | — | -10.2% | ||
| Q3 24 | — | -11.5% | ||
| Q2 24 | — | -7.6% | ||
| Q1 24 | — | -8.8% |
净利率BEAMEB
| Q4 25 | 214.1% | -11.1% | ||
| Q3 25 | — | 8.9% | ||
| Q2 25 | — | -2.9% | ||
| Q1 25 | — | -9.0% | ||
| Q4 24 | — | -11.0% | ||
| Q3 24 | — | -4.8% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | -5.2% |
每股收益（稀释后）BEAMEB
| Q4 25 | $2.53 | $-0.08 | ||
| Q3 25 | — | $0.06 | ||
| Q2 25 | — | $-0.02 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $299.9M |
| 总债务越低越好 | — | $144.4M |
| 股东权益账面价值 | $1.2B | $179.1M |
| 总资产 | $1.5B | $647.2M |
| 负债/权益比越低杠杆越低 | — | 0.81× |
8季度趋势，按日历期对齐
现金及短期投资BEAMEB
| Q4 25 | $1.2B | $299.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $441.5M | ||
| Q3 24 | — | $24.7M | ||
| Q2 24 | — | $56.7M | ||
| Q1 24 | — | $113.7M |
总债务BEAMEB
| Q4 25 | — | $144.4M | ||
| Q3 25 | — | $174.9M | ||
| Q2 25 | — | $241.3M | ||
| Q1 25 | — | $241.0M | ||
| Q4 24 | — | $240.7M | ||
| Q3 24 | — | $240.4M | ||
| Q2 24 | — | $358.7M | ||
| Q1 24 | — | $358.2M |
股东权益BEAMEB
| Q4 25 | $1.2B | $179.1M | ||
| Q3 25 | — | $189.1M | ||
| Q2 25 | — | $177.2M | ||
| Q1 25 | — | $173.3M | ||
| Q4 24 | — | $170.2M | ||
| Q3 24 | — | $179.8M | ||
| Q2 24 | — | $176.2M | ||
| Q1 24 | — | $184.1M |
总资产BEAMEB
| Q4 25 | $1.5B | $647.2M | ||
| Q3 25 | — | $744.6M | ||
| Q2 25 | — | $784.1M | ||
| Q1 25 | — | $812.3M | ||
| Q4 24 | — | $752.3M | ||
| Q3 24 | — | $817.4M | ||
| Q2 24 | — | $894.5M | ||
| Q1 24 | — | $952.2M |
负债/权益比BEAMEB
| Q4 25 | — | 0.81× | ||
| Q3 25 | — | 0.92× | ||
| Q2 25 | — | 1.36× | ||
| Q1 25 | — | 1.39× | ||
| Q4 24 | — | 1.41× | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 2.04× | ||
| Q1 24 | — | 1.95× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | $-60.8M |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | $-60.9M |
| 自由现金流率自由现金流/营收 | -76.3% | -82.8% |
| 资本支出强度资本支出/营收 | 3.3% | 0.0% |
| 现金转化率经营现金流/净利润 | -0.34× | — |
| 过去12个月自由现金流最近4个季度 | — | $17.6M |
8季度趋势，按日历期对齐
经营现金流BEAMEB
| Q4 25 | $-83.3M | $-60.8M | ||
| Q3 25 | — | $36.7M | ||
| Q2 25 | — | $-17.5M | ||
| Q1 25 | — | $59.4M | ||
| Q4 24 | — | $-45.3M | ||
| Q3 24 | — | $44.6M | ||
| Q2 24 | — | $-32.3M | ||
| Q1 24 | — | $68.6M |
自由现金流BEAMEB
| Q4 25 | $-87.0M | $-60.9M | ||
| Q3 25 | — | $36.6M | ||
| Q2 25 | — | $-17.5M | ||
| Q1 25 | — | $59.4M | ||
| Q4 24 | — | $-45.3M | ||
| Q3 24 | — | $44.4M | ||
| Q2 24 | — | $-32.4M | ||
| Q1 24 | — | $68.2M |
自由现金流率BEAMEB
| Q4 25 | -76.3% | -82.8% | ||
| Q3 25 | — | 51.1% | ||
| Q2 25 | — | -24.1% | ||
| Q1 25 | — | 80.4% | ||
| Q4 24 | — | -59.2% | ||
| Q3 24 | — | 57.1% | ||
| Q2 24 | — | -38.3% | ||
| Q1 24 | — | 79.1% |
资本支出强度BEAMEB
| Q4 25 | 3.3% | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.4% |
现金转化率BEAMEB
| Q4 25 | -0.34× | — | ||
| Q3 25 | — | 5.76× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -30.37× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
EB
| US | $52.0M | 71% |
| Other | $21.6M | 29% |
